Sol-Gel Technologies Pre-Tax Income 2016-2024 | SLGL

Sol-Gel Technologies pre-tax income from 2016 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Sol-Gel Technologies Annual Pre-Tax Income
(Millions of US $)
2023 $-27
2022 $-15
2021 $3
2020 $-29
2019 $-25
2018 $-33
2017 $-32
2016 $-21
2015 $-10
Sol-Gel Technologies Quarterly Pre-Tax Income
(Millions of US $)
2024-06-30 $2
2024-03-31 $-6
2023-12-31 $-5
2023-09-30 $-6
2023-06-30 $-6
2023-03-31 $-11
2022-12-31 $-6
2022-09-30 $-3
2022-06-30 $-0
2022-03-31 $-6
2021-12-31 $14
2021-09-30 $1
2021-06-30 $-8
2021-03-31 $-4
2020-12-31 $-6
2020-09-30 $-9
2020-06-30 $-7
2020-03-31 $-7
2019-12-31 $-7
2019-09-30 $-7
2019-06-30 $-5
2019-03-31 $-6
2018-12-31 $-13
2018-09-30 $-8
2018-06-30 $-7
2018-03-31 $-6
2017-12-31
2017-09-30
2017-06-30 $-6
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.016B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.612B 24.14
BridgeBio Pharma (BBIO) United States $5.094B 0.00
Bausch Health Cos (BHC) Canada $3.435B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.352B 13.96
Supernus Pharmaceuticals (SUPN) United States $2.021B 27.52
Taysha Gene Therapies (TSHA) United States $0.307B 50.00
Personalis (PSNL) United States $0.241B 0.00
Assembly Biosciences (ASMB) United States $0.106B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00